Recent insider selling at OptimizeRx, especially by Marion Odence-Ford, may worry potential investors. The absence of insider buying and insignificant share ownership by insiders hint at possible doubts about future performance.
OptimizeRx's high P/S ratio may suggest that investors anticipate a turnaround in the company's revenue performance. This could indicate shareholders' strong future revenue expectations.
The high P/S ratio at OptimizeRx suggests investors expect a reversal of the company's downtrend in revenue. Shareholders seem to hold stocks with hope for the company's promising future.
Investors at OptimizeRx might be anticipating a reversal in its poor revenue performance, hence the high P/S ratio. Shareholders potentially retain stocks expecting the company's bright future.
Investors at OptimizeRx may be expecting a turnaround in the company's poor revenue performance, hence the high P/S ratio. This could reflect shareholders' strong future revenue expectations.
Analysts exhibit growing optimism towards OptimizeRx, driven by notable hike in revenue expectations. The current market conditions indicate a potential good time for reassessing OptimizeRx.
OptimizeRx股票討論區
In reaction to earnings/guidance:
• $The Trade Desk(TTD.US)$+17%, $Workiva(WK.US)$ +15.3%, $Arlo Technologies(ARLO.US)$ +12%, $Array Technologies(ARRY.US)$ +10.3%, $Everbridge(EVBG.US)$ +9.7%, $Catalyst Pharmaceuticals(CPRX.US)$ +9.4%, $奧洛茲美醫療(HALO.US)$ +8.7%, $Velo3D(VLD.US)$ +7.6%, $CyberArk(CYBR.US)$ + 6.2%, $美國血液技術(HAE.US)$ +5.8%, $Jackson Financial(JXN.US)$ +5.7% (also increases dividend), $Axon Enterprise(AXON.US)$ +4.8%,...
• $Allogene Therapeutics(ALLO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX(CHX.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX運輸(CSX.US)$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
• $德希尼布FMC(FTI.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $諾福克南方(NSC.US)$ : Stifel Upgrades to Buy from Hold - PT $2...
• $Coupang(CPNG.US)$ : Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $28)
• $First Republic Bank(FRC.US)$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $188 (from $210)
• $Sitio Royalties(STR.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $43 (from $36)
Downgrades
• $Duck Creek Technologies(DCT.US)$ : JMP Securities Downgrades to Market Perform from Market Outperform
•...
$Coinbase(COIN.US)$
$Upstart(UPST.US)$
$OptimizeRx(OPRX.US)$
暫無評論